Research Article

Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug

Volume: 43 Number: 3 September 30, 2022
El Hassen Mokranı *, Amine Abdelazız , Naamane Akakba , Soumıa Tenıou , Rym Gouta Demmak , Abderrahmane Benseguenı
EN

Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug

Abstract

Cancer is a real public health problem that figures among the main causes of morbidity and mortality in the world. The Colchicine Binding Site (CBS) is an important pocket for potential tubulin polymerization destabilizers. Colchicine binding site inhibitors (CBSI) exhibit their biological effects by inhibiting tubulin assembly and suppressing microtubule formation. In order to identify new potent CBSI, molecular docking and drug likeness prediction were performed. In this context, a collection of 850 similar compounds to combretastatinA-4from PubChem database was docked into the CBS. Out of these, compounds S1 and S2 were found to have highest negative binding energy of -9.462 and -9.017 Kcal/mol respectively. Furthermore, these two compounds were predicted to have satisfying drug likeness properties, indicating that they might be promising lead compounds for further antitumor drug research.

Keywords

Cancer, Colchicine binding site, Glide, Molecular docking, Tubulin.

References

  1. [1] Üstün E., Şahin N., Molecular Docking Studies of N-Heterocyclic Carbene Molecules with Thioredoxin Reductase and DNA, Cumhuriyet Sci. J., 42(3) (2021) 656-662.
  2. [2] Sung H., Ferlay J., Siegel RL., Laversanne M., Soerjomataram I., Jemal A., Bray F., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: Cancer. J. Clin., 71 (3) (2021) 209-249.
  3. [3] International Agency for Research on Cancer, Global cancer observatory, GLOBOCAN 2020. Availabe at https://gco.iarc.fr/. Retrieved September 10, 2021.
  4. [4] Taperaa M., Kekeçmuhammed H., Tüzün B., Sarıpınar E., Koçyiğit UM., Yıldırım E., Doğan M., Zorlu Y. Synthesis, Carbonic Anhydrase Inhibitory Activity, Anticancer Activity and Molecular Docking Studies of New Imidazolyl Hydrazone Derivatives, J. Mol. Struct., 1269 (2022) 133816.
  5. [5] Sarkı G., Tüzün B., Ünlüer D., Kantekin H. Synthesis, characterization, chemical and biological activities of 4-(4-methoxyphenethyl)-5- benzyl-2-hydroxy-2H-1,2,4-triazole-3(4H)-one phthalocyanine derivatives, Inorg. Chim. Acta., Available online 30 July 2022, 121113.
  6. [6] Koçyiğit UM., Doğan M., Muğlu H., Taslimi P., Tüzün B., Yakan H., Bal H., Güzel E., Gülçin I. Determination of biological studies and molecular docking calculations of isatin-thiosemicarbazone hybrid compounds, J. Mol. Struct., 1264 (2022) 133249.
  7. [7] Cutts JH., Beer CT., Noble RL., Biological properties of Vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action, Cancer. Res., 20 (1960) 1023–31.
  8. [8] Person F., Wilczak W., Hube-Magg C., Burdelski C., Möller-Koop C., Simon R., Noriega M., Sauter G., Steurer S., Burdak-Rothkamm S., Jacobsen F., Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers, Tumor. Biol., 39(10) (2017) 1010428317712166.
  9. [9] Stengel C., Newman SP., Leese MP., Potter BVL., Reed MJ., Purohit A., Class III β-tubulin expression and in vitro resistance to microtubule targeting agents, Br. J. Cancer., 102(2) (2009) 316–324.
  10. [10] Massarotti A., Coluccia A., Silvestri R., Sorba G., Brancale A., The Tubulin Colchicine Domain: a Molecular Modeling Perspective, Chem.Med.Chem., 7(1) (2012) 33–42.
APA
Mokranı, E. H., Abdelazız, A., Akakba, N., Tenıou, S., Demmak, R. G., & Benseguenı, A. (2022). Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug. Cumhuriyet Science Journal, 43(3), 398-403. https://doi.org/10.17776/csj.1063966
AMA
1.Mokranı EH, Abdelazız A, Akakba N, Tenıou S, Demmak RG, Benseguenı A. Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug. CSJ. 2022;43(3):398-403. doi:10.17776/csj.1063966
Chicago
Mokranı, El Hassen, Amine Abdelazız, Naamane Akakba, Soumıa Tenıou, Rym Gouta Demmak, and Abderrahmane Benseguenı. 2022. “Molecular Docking and Drug-Likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug”. Cumhuriyet Science Journal 43 (3): 398-403. https://doi.org/10.17776/csj.1063966.
EndNote
Mokranı EH, Abdelazız A, Akakba N, Tenıou S, Demmak RG, Benseguenı A (September 1, 2022) Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug. Cumhuriyet Science Journal 43 3 398–403.
IEEE
[1]E. H. Mokranı, A. Abdelazız, N. Akakba, S. Tenıou, R. G. Demmak, and A. Benseguenı, “Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug”, CSJ, vol. 43, no. 3, pp. 398–403, Sept. 2022, doi: 10.17776/csj.1063966.
ISNAD
Mokranı, El Hassen - Abdelazız, Amine - Akakba, Naamane - Tenıou, Soumıa - Demmak, Rym Gouta - Benseguenı, Abderrahmane. “Molecular Docking and Drug-Likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug”. Cumhuriyet Science Journal 43/3 (September 1, 2022): 398-403. https://doi.org/10.17776/csj.1063966.
JAMA
1.Mokranı EH, Abdelazız A, Akakba N, Tenıou S, Demmak RG, Benseguenı A. Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug. CSJ. 2022;43:398–403.
MLA
Mokranı, El Hassen, et al. “Molecular Docking and Drug-Likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug”. Cumhuriyet Science Journal, vol. 43, no. 3, Sept. 2022, pp. 398-03, doi:10.17776/csj.1063966.
Vancouver
1.El Hassen Mokranı, Amine Abdelazız, Naamane Akakba, Soumıa Tenıou, Rym Gouta Demmak, Abderrahmane Benseguenı. Molecular Docking and Drug-likeness Prediction of New Potent Tubulin Colchicine Binding Site Inhibitors for Potential Antitumor Drug. CSJ. 2022 Sep. 1;43(3):398-403. doi:10.17776/csj.1063966

Cited By